New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi
STOCKHOLM, Oct. 5, 2026 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announcedthe publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with MOB-015 was achieved across the full...
Covered in this story
Call it yourself
No calls on $MOB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mobilicom →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.